Dumfries & Galloway Health Board
Prescribing Support Team

Nasal corticosteroid audit

Posted: 11 Apr 08 Edited: 8 Aug 18
Audits Eye, Ear, Nose and Throat

Beclometasone dipropionate exerts its effects by combining with a glucocorticoid receptor that is localised in the cytoplasm of target intranasal cells. The consequent activation of the glucocorticoid receptor complex can interact with cellular DNA thus enabling the regulation of cellular functions, in order to reduce levels of identified mediators (histamine, prosanoids and leukotrienes) in the nasal lavage fluid. The licensed indications for beclometasone dipropionate are prophylaxis and treatment of allergic, as well as vasomotor rhinitis. Given the high cost difference involved in nasal corticosteroids, it seems reasonable to identify patients currently on higher cost preparations and then switch the nasal corticosteroid to beclometasone dipropionate.